Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4202 |
Name | brain stem glioma |
Definition | A brain stem cancer that is characterized by mass lesion of the brainstem, associated cranial nerve nuclei and long tracts, has_material_basis_in abnormally proliferating cells, derives_from glial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer infratentorial cancer brain stem cancer brain stem glioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00879437 | Phase II | Bevacizumab Valproic acid | Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas | Completed | USA | 0 |
NCT01130077 | Phase I | Poly ICLC | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | Active, not recruiting | USA | 0 |
NCT01502917 | Phase I | Omburtamab I-124 | Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy | Completed | USA | 0 |
NCT01514201 | Phase Ib/II | Temozolomide Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | Completed | USA | 0 |
NCT01884740 | Phase Ib/II | Bevacizumab + Cetuximab | Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age | Terminated | USA | 0 |
NCT01922076 | Phase I | Adavosertib | WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | Completed | USA | CAN | 0 |
NCT02390843 | Phase I | Cyclophosphamide + Filgrastim + Simvastatin + Topotecan | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (AflacST1402) | Completed | USA | 0 |
NCT02420613 | Phase I | Vorinostat Temsirolimus | Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) | Active, not recruiting | USA | 0 |
NCT02607124 | Phase Ib/II | Ribociclib | Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Terminated | USA | 0 |
NCT02717455 | Phase I | Panobinostat | Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Completed | USA | 0 |
NCT02960230 | Phase Ib/II | H3.3K27M peptide vaccine + Montanide ISA 51 + Nivolumab + Poly ICLC + Tetanus Toxoid peptide H3.3K27M peptide vaccine + Montanide ISA 51 + Poly ICLC + Tetanus Toxoid peptide | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | Completed | USA | CHE | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03352427 | Phase II | Dasatinib + Everolimus | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations | Terminated | USA | 0 |
NCT03355794 | Phase I | Everolimus + Ribociclib | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Completed | USA | 0 |
NCT03387020 | Phase I | Ribociclib Everolimus + Ribociclib | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | Completed | USA | 0 |
NCT03389802 | Phase I | Sotigalimab | Phase I Study of APX005M in Pediatric CNS Tumors | Active, not recruiting | USA | 0 |
NCT03566199 | Phase Ib/II | MTX110 | MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015) | Completed | USA | 0 |
NCT03598244 | Phase I | Savolitinib | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | Recruiting | USA | CAN | 0 |
NCT03605550 | Phase I | Unesbulin | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Active, not recruiting | USA | 0 |
NCT03620032 | Phase II | Nimotuzumab + Vinorelbine | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses (DIPG) | Active, not recruiting | ITA | 0 |
NCT03632317 | Phase II | Everolimus + Panobinostat | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | Withdrawn | USA | 0 |
NCT03652545 | Phase I | MultiTAA-specific T cells | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) | Recruiting | USA | 0 |
NCT03696355 | Phase I | GDC-0084 | Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas | Completed | USA | 0 |
NCT04049669 | Phase II | Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Recruiting | USA | 0 |
NCT04099797 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Recruiting | USA | 0 |
NCT04185038 | Phase I | SCRI-CARB7H3 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Recruiting | USA | 0 |
NCT04196413 | Phase I | Cyclophosphamide + Fludarabine GD2 CAR T cells | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) | Recruiting | USA | 0 |
NCT04264143 | Phase I | MTX110 | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | Completed | USA | 0 |
NCT04295759 | Phase I | INCB7839 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | Active, not recruiting | USA | 0 |
NCT04341311 | Phase I | Marizomib + Panobinostat Marizomib | Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG) | Terminated | USA | 0 |
NCT04617002 | Expanded access | ONC201 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas | Available | USA | 0 |
NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Recruiting | USA | DEU | CAN | AUS | 0 |
NCT04771897 | Phase I | BXQ-350 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER) | Active, not recruiting | USA | 0 |
NCT04943848 | Phase I | rHSC-DIPGVax Balstilimab + rHSC-DIPGVax Balstilimab + rHSC-DIPGVax + Zalifrelimab | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | Recruiting | USA | 0 |
NCT05009992 | Phase II | GDC-0084 + ONC201 ONC201 + Panobinostat | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Recruiting | USA | NZL | NLD | ISR | CHE | AUS | 0 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | NZL | CAN | AUS | 0 |
NCT05768880 | Phase I | SC-CAR4BRAIN | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | Recruiting | USA | 0 |
NCT05843253 | Phase II | Everolimus + Ribociclib | Study of Ribociclib and Everolimus in HGG and DIPG | Recruiting | USA | NLD | GBR | DEU | CAN | AUS | 0 |
NCT05956821 | Phase Ib/II | Bevacizumab + Cetuximab | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | Recruiting | USA | 0 |